%0 Systematic Review
%T SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022).
%A Ayala de la Peña F
%A Antolín Novoa S
%A Gavilá Gregori J
%A González Cortijo L
%A Henao Carrasco F
%A Martínez Martínez MT
%A Morales Estévez C
%A Stradella A
%A Vidal Losada MJ
%A Ciruelos E
%J Clin Transl Oncol
%V 25
%N 9
%D 2023 Sep 16
%M 37326826
%F 3.34
%R 10.1007/s12094-023-03215-4
%X Breast cancer is the leading cause of cancer in women in Spain and its annual incidence is rapidly increasing. Thanks to the screening programs in place, nearly 90% of breast cancer cases are detected in early and potentially curable stages, despite the COVID-19 pandemic possibly having impacted these numbers (not yet quantified). In recent years, locoregional and systemic therapies are increasingly being directed by new diagnostic tools that have improved the balance between toxicity and clinical benefit. New therapeutic strategies, such as immunotherapy, targeted drugs, and antibody-drug conjugates have also improved outcomes in some patient subgroups. This clinical practice guideline is based on a systematic review of relevant studies and on the consensus of experts from GEICAM, SOLTI, and SEOM.